Eradication of bacterial biofilm using anti-amyloid monoclonal antibodies

Patent metadata

Field	Value
Publication number	US-12202887-B2
Application number	US-202217579952-A
Country	US
Kind code	B2
Filing date	Jan 20, 2022
Priority date	May 25, 2018
Publication date	Jan 21, 2025
Grant date	Jan 21, 2025

Abstract

The present invention features compositions comprising an anti-amyloid antibody and methods of treating microbial infection and treating or preventing microbial biofilms using the composition.

First claim

What is claimed is:

1. An antibody or antibody fragment thereof comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:9; a heavy chain CDR2 comprising amino acid sequence of SEQ ID NO:13; a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:17; a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 39; a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 43; and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 47.

2. The antibody or antibody fragment thereof of claim 1 , encoded by a nucleic acid sequence comprising a nucleic acid sequence encoding a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3, wherein the heavy chain CDR1 is encoded by a nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 8; wherein the heavy chain CDR2 is encoded by a nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 12; and wherein the heavy chain CDR3 is encoded by a nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO:16.

3. The antibody or antibody fragment thereof of claim 1 , encoded by a nucleic acid sequence encoding a light chain CDR1, a light chain CDR2, and a light chain CDR3, wherein the light chain CDR1 is encoded by a nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO:38; wherein the light chain CDR2 is encoded by a nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO: 42; and wherein the light chain CDR3 is encoded by a nucleic acid sequence comprising the nucleic acid sequence of SEQ ID NO:46.

4. The antibody of claim 1 wherein the antibody is in a format selected from the group consisting of scfv and Fv fragment.

5. An isolated polypeptide comprising the amino acid sequence SEQ ID NO:9, SEQ ID NO:13, SEQ ID NO:17, SEQ ID NO:39, SEQ ID NO: 43, and SEQ ID NO:47.

6. The isolated polypeptide of claim 5 wherein the polypeptide is in a format selected from the group consisting of scfv and Fv fragment.

7. An antibody or antibody fragment thereof comprising a heavy and light chain selected from the group consisting of:
a) a heavy chain amino acid sequence comprising SEQ ID NO:2 and a light chain amino acid sequence comprising SEQ ID NO:35;
b) a heavy chain amino acid sequence comprising SEQ ID NO:61 and a light chain amino acid sequence comprising SEQ ID NO:63; and
c) a heavy chain amino acid sequence comprising SEQ ID NO:57 and a light chain amino acid sequence comprising SEQ ID NO:59.

8. The antibody or antibody fragment of claim 7 , wherein the heavy and light chain is encoded by a nucleic acid sequence selected from the group consisting of:
a) a heavy chain nucleic acid sequence comprising SEQ ID NO:1 and a light chain nucleic acid sequence comprising SEQ ID NO:34;
b) a heavy chain nucleic acid sequence comprising SEQ ID NO:60 and a light chain nucleic acid sequence comprising SEQ ID NO:62; and
c) a heavy chain nucleic acid sequence comprising SEQ ID NO:56 and a light chain nucleic acid sequence comprising SEQ ID NO:58.

9. An antibody or antibody fragment thereof comprising a heavy chain CDR1, wherein the heavy chain CDR1 comprises amino acid residues 23-35 of SEQ ID NO: 57; a heavy chain CDR2, wherein the heavy chain CDR2 comprises amino acid residues 50-59 of SEQ ID NO: 57; a heavy chain CDR3, wherein the heavy chain CDR3 comprises amino acid residues 97-116 of SEQ ID NO: 57; a light chain CDR1, wherein the light chain CDR1 comprises amino acid residues 24-34 of SEQ ID NO: 59; a light chain CDR2, wherein the light chain CDR2 comprises amino acid residues 49-56 of SEQ ID NO: 59; and a light chain CDR3, wherein the light chain CDR3 comprises amino acid residues 89-97 of SEQ ID NO: 59.

10. The antibody or antibody fragment thereof of claim 9 , encoded by a nucleic acid sequence comprising a nucleic acid sequence encoding a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3, wherein the heavy chain CDR1 is encoded by a nucleic acid sequence comprising nucleotides 67-105 of SEQ ID NO: 56; wherein the heavy chain CDR2 is encoded by a nucleic acid sequence comprising nucleotides 148-177 of SEQ ID NO: 56; and wherein the heavy chain CDR3 is encoded by a nucleic acid sequence comprising nucleotides 289-348 of SEQ ID NO: 56.

11. The antibody or antibody fragment thereof of claim 9 , encoded by a nucleic acid sequence comprising a nucleic acid sequence encoding a light chain CDR1, a light chain CDR2, and a light chain CDR3, wherein the light chain CDR1 is encoded by a nucleic acid sequence comprising nucleotides 70-102 of SEQ ID NO: 58; wherein the light chain CDR2 is encoded by a nucleic acid sequence comprising nucleotides 145-168 of SEQ ID NO: 58; and wherein the light chain CDR3 is encoded by a nucleic acid sequence comprising nucleotides 265-291 of SEQ ID NO: 58.

12. An antibody or antibody fragment thereof comprising a heavy chain CDR1, wherein the heavy chain CDR1 comprises amino acid residues 23-35 of SEQ ID NO: 61; a heavy chain CDR2, wherein the heavy chain CDR2 comprises amino acid residues 50-59 of SEQ ID NO: 61; a heavy chain CDR3, wherein the heavy chain CDR3 comprises amino acid residues 97-118 of SEQ ID NO: 61, a light chain CDR1, wherein the light chain CDR1 comprises amino acid residues 24-34 of SEQ ID NO: 63; a light chain CDR2, wherein the light chain CDR2 comprises amino acid residues 49-56 of SEQ ID NO: 63; and a light chain CDR3, wherein the light chain CDR3 comprises amino acid residues 89-97 of SEQ ID NO: 63.

13. The antibody or antibody fragment thereof of claim 12 , encoded by a nucleic acid sequence comprising a nucleic acid sequence encoding a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3, wherein the heavy chain CDR1 is encoded by a nucleic acid sequence comprising nucleotides 67-105 of SEQ ID NO: 60; wherein the heavy chain CDR2 is encoded by a nucleic acid sequence comprising nucleotides 148-177 of SEQ ID NO: 60; and wherein the heavy chain CDR3 is encoded by a nucleic acid sequence comprising nucleotides 289-354 of SEQ ID NO: 60.

14. The antibody or antibody fragment thereof of claim 12 , encoded by a nucleic acid sequence comprising a nucleic acid sequence encoding a light chain CDR1, a light chain CDR2, and a light chain CDR3, wherein the light chain CDR1 is encoded by a nucleic acid sequence comprising nucleotides 70-102 of SEQ ID NO: 62; wherein the light chain CDR2 is encoded by a nucleic acid sequence comprising nucleotides 145-168 of SEQ ID NO: 62; and wherein the light chain CDR3 is encoded by a nucleic acid sequence comprising nucleotides 265-291 of SEQ ID NO: 62.

Assignees

• Univ Temple
• Lankenau Institute Of Medical Res

Inventors

• Wilson Cagla Tukel
• Dessain Scott

Classifications

• C07K16/1232

  Escherichia (G) · CPC title

• C07K16/1228 Primary

  Enterobacterales (O), e.g. Citrobacter (G), Serratia (G), Proteus (G), Providencia (G), Morganella (G) or Yersinia (G) · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• A61P31/00

  Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics · CPC title